Machine learning (ML) enables modeling of quantitative structure-activity relationships (QSAR) and compound potency predictions. Recently, multi-target QSAR models have been gaining increasing attention. Simultaneous compound potency predictions for multiple targets can be carried out using ensembles of independently derived target-based QSAR models or in a more integrated and advanced manner using multi-target deep neural networks (MT-DNNs). Herein, single-target and multi-target ML models were systematically compared on a large scale in compound potency value predictions for 270 human targets. By design, this large-magnitude evaluation has been a special feature of our study. To these ends, MT-DNN, single-target DNN (ST-DNN), support vector regression (SVR), and random forest regression (RFR) models were implemented. Different test systems were defined to benchmark these ML methods under conditions of varying complexity. Source compounds were divided into training and test sets in a compound- or analog series-based manner taking target information into account. https://www.selleckchem.com/products/FK-506-(Tacrolimus).html Data partitioning approaches used for model training and evaluation were shown to influence the relative performance of ML methods, especially for the most challenging compound data sets. For example, the performance of MT-DNNs with per-target models yielded superior performance compared to single-target models. For a test compound or its analogs, the availability of potency measurements for multiple targets affected model performance, revealing the influence of ML synergies.The importance of hepatocellular carcinoma (HCC) caused by obesity has been emphasized. Many studies have shown that weight fluctuations as well as high BMI are associated with various adverse outcomes. In this study, we investigated the relationship between weight fluctuation and HCC in general populations drawn from a nationwide population-based cohort.
A population-based cohort study including 8,001,829 subjects participating in more than three health examinations within 5years from the index year were followed until the end of 2017. The degree of weight fluctuation and incidence of HCC during the period were evaluated.
When we classified groups according to baseline body mass index (BMI) level, the highest risk for HCC was observed in subjects with BMI of 30 or greater (adjusted hazard ratio [aHR] 1.40, 95% confidence interval [CI] 1.27-1.54). Also, increasing trends for the relationship between weight fluctuation and HCC were observed in multivariable Cox proportional analyses. The risk of HCC increased by 16% (aHR 1.16, 95% CI 1.12-1.20) for the highest quartile of weight fluctuation relative to the lowest quartile. These findings were consistent regardless of the baseline BMI or other metabolic factors. However, these effects of weight fluctuation on HCC were not observed in liver cirrhosis or viral hepatitis subgroups.
Weight fluctuation is an independent predictor of HCC. In the absence of liver cirrhosis or chronic hepatitis, the impact of weight fluctuation on HCC is further emphasized. These results suggest maintaining steady weight is recommended to reduce the risk of HCC.
Weight fluctuation is an independent predictor of HCC. In the absence of liver cirrhosis or chronic hepatitis, the impact of weight fluctuation on HCC is further emphasized. These results suggest maintaining steady weight is recommended to reduce the risk of HCC.Limited information is available on the association between depression and viral suppression among people living with HIV (PLH) in sub-Saharan Africa. We conducted a prospective cohort study of 3996 adults initiating antiretroviral therapy (ART) in Dar es Salaam, Tanzania. Log-binomial models were used to assess the association between depression and the risk of an unsuppressed viral load (&gt;?400 copies/mL) after 6 months of ART. Women who had depression at both initiation and after 6 months of treatment had 1.94 times (95% CI 1.22, 3.09; z?=?2.78, p? less then ?0.01) the risk of an unsuppressed viral load after 6 months of treatment as compared to women who did not have depression at either time point. Men with the top tertile of depressive symptoms after 6 months of treatment had 1.58 times the risk of an unsuppressed viral load (95% CI 1.04, 2.38; z?=?2.15, p?=?0.03) as compared to the lowest tertile. Research should be pursued on interventions to prevent and address depression among adults initiating ART to potentially support achievement of viral suppression.In recent axSpAx patients with remission lasting at least 3months and later followed-up monthly for a median of 8months, we compared the predictive value of baseline MRI of sacroiliac joints and constructed a nomogram model for predicting flare.
This study included 251 patients with axial spondyloarthritis, according to the ASAS axSpA classification criteria, who achieved Low Disease Activity (ASDAS) and underwent MRI examination. A total of 144 patients from the First Affiliated Hospital of Xiamen University were used as the nomogram training set; 107 from the First Affiliated Hospital of Fujian Medical University were for external validation.
The median time of relapse was 8.705months (95% CI 8.215-9.195) and 7.781months (95% CI 7.075-8.486) for MRI-positive patients and 9.8months (95% CI 9.273-10.474) for MRI negative patients, respectively. Both active sacroiliitis on MRI (HR 1.792, 95% CI 1.230-2.611) and anti-TNF-α treatments (HR 0.507, 95% CI 0.349-0.736) were significantly associated with disease flares. Gender, disease duration, HLA-B27, MRI, and anti-TNF-α treatment were selected as predictors of the nomogram. The areas under the ROC curve (AUROCs) of the 1-year remission probability in the training and validation groups were 0.71 and 0.729, respectively. Nomogram prediction models present better AUROCs, C-indices, and decision curve analysis cure than the clinical experience model.
Active sacroiliitis in MRI requires weighting in order to estimate remission and disease flares, when axSpA patients achieve low disease activity. The simple nomogram might be able to discriminate and calibrate in clinical practice.
ClinicalTrials, NCT03425812, Registered 8 February 2018, https//clinicaltrials.gov.
ClinicalTrials, NCT03425812, Registered 8 February 2018, https//clinicaltrials.gov.